ERBB2 and neoplasm: Since clinicopathological data for tumor samples including ERalpha, PR and HER2 protein expression and also clinical staging, histological grading, lymph node and menopausal statuses were available, we further examined the mRNA expression of RBCK1, RNF31 and SHARPIN in relation to these data.